ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1603093
Systematic Bioinformatics Analysis Identifies Shikonin as a Novel mTOR Pathway Inhibitor in Triple-Negative Breast Cancer Progression
Provisionally accepted- 1Tangdu Hospital, Air Force Medical University, Xi'an, China
- 2Fudan University, Shanghai, Shanghai Municipality, China
- 3Peking University, Beijing, Beijing Municipality, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its resistance to conventional therapies and poor prognosis. Shikonin, a natural compound derived from Lithospermum erythrorhizon, has demonstrated antitumor potential in TNBC, though its molecular mechanisms remain unclear. In this study, shikonin’s antitumor effects were systematically evaluated using colony formation, wound-healing assays, transcriptomic profiling, and molecular docking. Results demonstrated that shikonin markedly inhibited TNBC cell proliferation and migration. Transcriptomic analysis identified downregulation of key mTOR signaling pathway genes (MTOR, CCND1, CDK6) post-treatment. Molecular docking confirmed direct binding between shikonin and the mTOR protein, suggesting mTOR pathway inhibition as a critical mechanism. Of note, the PI3K/AKT/mTOR axis is frequently hyperactivated in TNBC to regulate tumor proliferation and survival, yet existing mTOR inhibitors show limited efficacy in this subtype due to feedback activation of compensatory pathways and off - target effects that reduce their specificity for TNBC. Our findings highlight shikonin’s ability to target mTOR-related signaling, offering a novel strategy for TNBC treatment. This study provides foundational insights into shikonin’s molecular action, emphasizing its potential as a natural mTOR inhibitor tailored for TNBC. Further exploration of shikonin’s therapeutic applications could address the urgent need for targeted therapies against this aggressive breast cancer subtype, bridging gaps in current clinical approaches.
Keywords: Triple-negative breast cancer, Shikonin, molecular docking, Bioinformatic analysis, MTOR signaling
Received: 31 Mar 2025; Accepted: 06 Aug 2025.
Copyright: © 2025 Liang, Liu, Liu, Yao, Wu, Li, Fu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ying Liang, Tangdu Hospital, Air Force Medical University, Xi'an, China
Ming-gao Zhao, Tangdu Hospital, Air Force Medical University, Xi'an, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.